Androgen Deprivation Therapy for Prostate Cancer Did Not Increase the Risk of Retinal Vascular Occlusion: A Population-Based Cohort Study

Hsin-Le Lin, Chia-Yi Lee, Jing-Yang Huang, Po-Chen Tseng and Shun-Fa Yang
Additional contact information
Hsin-Le Lin: Department of Ophthalmology, Taipei City Hospital, Renai Branch, Taipei 106243, Taiwan
Chia-Yi Lee: Department of Ophthalmology, Nobel Eye Institute, Taipei 106074, Taiwan
Jing-Yang Huang: Department of Medical Research, Chung Shan Medical University Hospital, Taichung 402367, Taiwan
Po-Chen Tseng: Department of Ophthalmology, Taipei City Hospital, Renai Branch, Taipei 106243, Taiwan
Shun-Fa Yang: Department of Medical Research, Chung Shan Medical University Hospital, Taichung 402367, Taiwan

IJERPH, 2022, vol. 19, issue 4, 1-10

Abstract: This study aimed to evaluate the effect of androgen deprivation therapy (ADT) on retinal vascular occlusion (RVO) development in patients with prostate cancer, using data from Taiwan’s National Health Insurance Research Database. A total of 1791, 1791, and 3582 patients were enrolled in the prostate cancer with ADT group, prostate cancer without ADT group, and the control group, respectively. The primary outcome was RVO occurrence, according to diagnostic codes. Cox proportional hazard regression was used to determine the adjusted hazard ratio (aHR) and 95% confidence interval (CI) of ADT and other covariates for RVO incidence. After a follow-up interval of up to 18 years, the patients with prostate cancer who received ADT showed significantly lower RVO incidence than the control group (aHR: 0.191, 95% CI: 0.059–0.621, p = 0.0059), after adjusting for multiple confounders. Hypertension was related to higher RVO incidence (aHR: 2.130, 95% CI: 1.127–4.027, p = 0.0199). Our overall results showed that using ADT for prostate cancer did not lead to a greater risk of RVO development. In fact, the patients with prostate cancer who received ADT had lower RVO incidence than those who did not receive ADT.

Keywords: androgen deprivation therapy; retinal vascular occlusion; prostate cancer (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/4/2268/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/4/2268/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:4:p:2268-:d:751365

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().